Related Experiment Videos
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens
Yun-Song Wang1, Bi-Tao Li2, Shi-Xi Liu1
1Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, School of Chemical Science and Technology, Yunnan University , Kunming 650091, People's Republic of China.
Journal of Natural Products
|April 4, 2017
Summary
Researchers discovered two novel compounds, anisucoumaramide and anisumic acid, from Clausena anisum-olens. Anisucoumaramide exhibits potent and selective inhibition of monoamine oxidase B (MAO-B).
Area of Science:
- Natural Product Chemistry
- Organic Chemistry
- Biochemistry
Background:
- Clausena anisum-olens is a plant source of bioactive natural products.
- Coumarins and truxinate derivatives are classes of compounds with diverse biological activities.
Purpose of the Study:
- To isolate and characterize new chemical entities from Clausena anisum-olens.
- To investigate the structural and stereochemical features of the isolated compounds.
- To evaluate the inhibitory activity of the isolated compounds against monoamine oxidase B (MAO-B).
Main Methods:
- Isolation and purification of compounds using chromatographic techniques.
- Structure elucidation using Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS).
- Determination of absolute configuration via Electronic Circular Dichroism (ECD) spectroscopy.
- Enzyme inhibition assays for MAO-B activity.
Main Results:
- Two new compounds, anisucoumaramide (1) and anisumic acid (2), were identified.
- Anisucoumaramide (1) possesses a unique terpenoidal side chain structure, deviating from the isoprene rule.
- Anisumic acid (2) is the first reported δ-truxinate derivative from the Clausena genus.
- Anisucoumaramide (1) demonstrated high selectivity and nanomolar inhibitory activity against MAO-B.
Conclusions:
- The study reports novel natural products with unique structural characteristics.
- Anisucoumaramide (1) represents a significant finding due to its unusual biosynthetic pathway.
- The selective MAO-B inhibition by anisucoumaramide (1) suggests potential therapeutic applications.